Press Releases

Tubulis Welcomes Magdalena Zikmundova as Associate Medical Director and Armin Weidmann as Vice President Quality

We continue to expand our team with key additions to bring our unique ADCs to the clinic.

Magdalena Zikmundova is an accomplished, board-certified hematologist and translational scientist from Charles University, Prague. She held prior positions as Clinical Research Fellow at Roche in Switzerland and as Clinical Program Lead for Tafasitamab (Monjuvi®) at MorphoSys. Her passion and focus of interest is to develop innovative therapies for patients with lymphomas and to improve outcomes for patients with aggressive lymphomas such as T- and B-cell lymphomas. Magdalena joins us as Associate Medical Director, and her profound scientific and clinical knowledge in the area of hematologic malignancies as well as the development and conduct of clinical trials will significantly contribute to the development and evaluation of our next-generation ADC candidates targeting hematologic and solid tumors.

Armin Weidmann joins Tubulis as Vice President Quality. He brings more than 20 years of expertise in the biotech industry with extensive leadership experience in the areas of GxP quality management, compliance management and corporate internal audit function. He will use long-standing know-how to advance our ADC programs into the clinic and oversee clinical trial processes, the next important steps on our mission to deliver better outcomes for cancer patients.


For Tubulis
Dominik Schumacher,
CEO & Co-Founder
Phone: +49 175 800 5594

Media Requests for Tubulis
Trophic Communications
Stephanie May or Marie Weickert
Phone: + 49 171 185 5682

Share Article

More Press Releases

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024